Leonard Reyno - 14 Feb 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Medical Officer
Signature
/s/ Shagha Russell, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
14 Feb 2025
Net transactions value
-$16,361
Form type
4
Filing time
18 Feb 2025, 16:54:28 UTC
Previous filing
11 Jul 2024
Next filing
15 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $0 +87,100 +95% $0.000000 178,909 14 Feb 2025 Direct F1
transaction CCCC Common Stock Tax liability $16,361 -5,145 -2.9% $3.18 173,764 14 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +130,600 $0.000000 130,600 14 Feb 2025 Common Stock 130,600 $3.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
F3 The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.